Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

Summary

This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI), and ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI) are effective as non-invasive methods for assessing the cells and proteins that surround and interact with tumor cells (the tumor immune microenvironment) in patients with glioblastoma. Researchers understand that some types of brain tumors are harder to treat than others, but the reasons for this are not known in many cases. CEST MRI uses differences in the tissue microenvironment, like protein concentration or intracellular pH, to generate contrast differences. DR-CSI detects microstructural changes in tissue associated with immune cells infiltrating the tumor. Fe-MRI uses ferumoxytol as a contrast agent with MRI. Contrast agents are substances that are injected into the body and taken up by certain tissues, making the tissues easier to see in imaging scans. More advanced imaging techniques like CEST, DR-CSI, and Fe-MRI may offer less invasive methods than surgery or biopsy for helping researchers understand the tumor immune microenvironment in patients with glioblastoma, which may help researchers determine why some tumors are more resistant to treatment.

Interventions

• Biospecimen Collection · PROCEDURE

  Undergo collection of blood samples

• Chemical Exchange Saturation Transfer Magnetic Resonance Imaging · PROCEDURE

  Undergo CEST MRI

• Diffusion-Relaxation Correlation Spectrum Imaging · PROCEDURE

  Undergo DR-CSI

• Electronic Health Record Review · OTHER

  Ancillary studies

• Ferumoxytol · DRUG

  Given IV

• Magnetic Resonance Imaging · RADIATION

  Undergo MRI

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Male or female ≥ 18 years of age
* Documentation of a confirmed or suspected diagnosis of glioblastoma
* The participant is scheduled to undergo standard of care surgical tumor resection and/or biopsy
* The participant has a measurable contrast-enhancing lesion (\> 1ml) based on the most recent MRI prior to resection/biopsy

Exclusion Criteria:

* Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
* Individuals who cannot tolerate MRI scan, or with contraindication to 3-Tesla (3T) MRI
* Any abnormalities that would be a contraindication to iron-oxide nanoparticle-based contrast agent. Medical history will be gathered from the patient and clinical chart. The information will be reviewed with medical professionals (Doctor of Medicine \[MD\]) to determine the eligibility of the patient

Sites (1)

• UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California · RECRUITING